DRTS Stock Overview
A clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Alpha Tau Medical Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.13 |
| 52 Week High | US$3.40 |
| 52 Week Low | US$1.75 |
| Beta | 0.80 |
| 1 Month Change | 4.33% |
| 3 Month Change | 36.68% |
| 1 Year Change | -5.44% |
| 3 Year Change | -68.35% |
| 5 Year Change | n/a |
| Change since IPO | -69.01% |
Recent News & Updates
Recent updates
Alpha Tau Medical (NASDAQ:DRTS) Has Debt But No Earnings; Should You Worry?
May 25
Alpha Tau Medical (NASDAQ:DRTS) Is In A Good Position To Deliver On Growth Plans
Nov 08Alpha Tau director gives up board seat to take up chief commercial officer role
Sep 02Alpha Tau Medical GAAP EPS of -$0.03
Aug 25Alpha Tau: Treating Cancer With Precision Alpha Radiation
Apr 12Shareholder Returns
| DRTS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.0% | -0.3% | -0.2% |
| 1Y | -5.4% | 11.3% | 25.8% |
Return vs Industry: DRTS underperformed the US Medical Equipment industry which returned 11.3% over the past year.
Return vs Market: DRTS underperformed the US Market which returned 25.8% over the past year.
Price Volatility
| DRTS volatility | |
|---|---|
| DRTS Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DRTS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DRTS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 121 | Uzi Sofer | www.alphatau.com |
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company’s Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. Fundamentals Summary
| DRTS fundamental statistics | |
|---|---|
| Market cap | US$218.86m |
| Earnings (TTM) | -US$29.64m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs DRTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRTS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.64m |
| Earnings | -US$29.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.9% |
How did DRTS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 16:20 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alpha Tau Medical Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |
| Neena Bitritto-Garg | Citigroup Inc |